Table 1.
Baseline patient characteristics
| Ibandronate 0.5 mg (n = 376) | Ibandronate 1 mg (n = 382) | Risedronate (n = 376) | |
|---|---|---|---|
| Women, n (%) | 356 (94.7) | 354 (92.7) | 343 (91.2) |
| Mean age, years (SD) | 72.9 (6.34) | 72.2 (6.38) | 73.0 (6.29) |
| Aged 60–74 years, n (%) | 219 (58.2) | 245 (64.1) | 227 (60.4) |
| Aged ≥ 75 years, n (%) | 157 (41.8) | 137 (35.9) | 149 (39.6) |
| Mean weight, kg (SD) | 50.6 (8.00) | 50.9 (7.36) | 51.1 (8.35) |
| Mean height, cm (SD) | 149.2 (6.66) | 149.5 (6.56) | 149.4 (6.70) |
| Mean BMD T-score (SD) | |||
| Lumbar spine (L2–L4) | −2.71 (1.01) | −2.68 (1.01) | −2.59 (1.06) |
| Femoral neck | −2.48 (0.73) | −2.41 (0.80) | −2.53 (0.79) |
| Total hip | −2.17 (0.87) | −2.09 (0.86) | −2.18 (0.86) |
| Prevalent vertebral fractures, n (%) | |||
| 1 | 186 (49.5) | 184 (48.2) | 183 (48.7) |
| 2 | 97 (25.8) | 106 (27.7) | 95 (25.3) |
| >2 | 93 (24.7) | 92 (24.1) | 98 (26.1) |
| Mean uCTX, µg/mmol CR (SD) | 382.4 (226.2) | 368.6 (209.9) | 373.2 (261.0) |
| Mean uNTX, nM BCE/mM CR (SD) | 73.6 (39.31) | 69.4 (35.42) | 68.9 (35.16) |
| Mean BALP, IU/L (SD) | 33.6 (13.15) | 33.9 (13.11) | 32.4 (11.96) |
| Mean 25-OH vitamin D, ng/mL (SD) | 19.6 (6.44) | 20.0 (6.69) | 19.7 (6.56) |
BALP bone-specific alkaline phosphatase, BCE bovine collagen equivalent, BMD bone mineral density, CR creatinine, SD standard deviation, uCTX creatinine-corrected urinary collagen type 1 cross-linked C-telopeptide, uNTX creatinine-corrected urinary collagen type 1 cross-linked N-telopeptide